Caredx, Inc. (CDNA) Stock Price & Analysis
Caredx, Inc. (CDNA) rose 3.64% to USD 22.75 as of June 10, 2026 at 01:55 UTC, according to Nexqual real-time market data.
CDNA last closed at USD 21.95; the session ranged USD 21.65–23.05 on volume of 724,460 shares. Market capitalization is $1.18B, with a 52-week range of USD 10.96–24.02 (NGM). Source: Nexqual, June 10, 2026 at 01:55 UTC.
Key Statistics (as of June 10, 2026 at 01:55 UTC)
| Price | USD 22.75 |
|---|---|
| Change | ▲ 3.64% (up) |
| Previous Close | USD 21.95 |
| Open | USD 22.27 |
| Day Range | USD 21.65 – 23.05 |
| 52-Week Range | USD 10.96 – 24.02 |
| Volume | 724,460 shares |
| Market Cap | $1.18B |
| Exchange | NGM |
Technical Analysis (CDNA)
Nexqual's technical model rates CDNA "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 01:55 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 58.62 (neutral) |
| vs SMA50 | Above (USD 20.49) |
| MACD | 0.56 (positive) |
Analyst Ratings (CDNA)
Wall Street analysts rate CDNA "Buy" based on 5 analysts, with a mean price target of USD 25.8 (range USD 21–28), per Nexqual as of June 10, 2026 at 01:55 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 25.8 |
| High Target | USD 28 |
| Low Target | USD 21 |
| Buy / Hold / Sell | 3 / 4 / 0 |
Earnings (CDNA)
| Next Earnings Date | 2026-04-28 |
|---|---|
| EPS Estimate | USD 0.23 |
| Revenue Estimate | $114.05M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.34 vs est 0.13 ▲ beat |
| 2025-12-31 | USD 0.12 vs est 0.23 ▼ miss |
| 2025-09-30 | USD 0.28 vs est 0.14 ▲ beat |
| 2025-06-30 | USD 0.1 vs est 0.12 ▼ miss |
Source: Nexqual, June 10, 2026 at 01:55 UTC.
Financials & Fundamentals (CDNA)
| Total Revenue | $412.82M |
|---|---|
| Revenue Growth (YoY) | +39.00% |
| Gross Margin | +68.88% |
| Operating Margin | +1.53% |
| Profit Margin | -1.98% |
| ROE | -2.37% |
| Debt / Equity | 7.81 |
| Current Ratio | 3.4 |
| Total Cash | $187.18M |
| Total Debt | $24.50M |
| Free Cash Flow | $70.14M |
Source: Nexqual, June 10, 2026 at 01:55 UTC.
Financial Health Score (CDNA)
Nexqual rates Caredx, Inc.'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 01:55 UTC.
| Growth | Solid — Revenue +14% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 69%, operating 2% |
| Balance Sheet | Strong — $187M cash vs $24M debt, net cash position |
| Cash Flow | Strong — FCF $70M, 18% margin |
| Efficiency | Critical — ROE -2%, ROA -1.8% |
Ownership (CDNA)
| Insider Ownership | +3.38% |
|---|---|
| Institutional Ownership | +101.84% |
| Shares Outstanding | 51.66M |
| Float | 49.29M |
| Short % of Float | +12.56% |
Source: Nexqual, June 10, 2026 at 01:55 UTC.
Leadership (CDNA)
Caredx, Inc. is led by John Walter Hanna (age 45), President, CEO & Director, per Nexqual as of June 10, 2026 at 01:55 UTC.
| President, CEO & Director | John Walter Hanna (age 45) |
|---|---|
| CFO & COO | Keith S. Kennedy C.F.A. (age 55) |
| Chief Technology Officer | Kashif Rathore |
| Chief Scientific Officer | Robert N. Woodward |
| Vice President of Investor Relations | Tina Jacobsen |
Major Backers & Investors (CDNA)
Notable institutional backers of Caredx, Inc. include ARK Invest, BAMCO Inc., BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd., according to Nexqual as of June 10, 2026 at 01:55 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 7.62% |
| BAMCO Inc. | 6.46% |
| BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd. | 4.63% |
| Deerfield Management Company, L.P | 4.24% |
| Braidwell LP | 4.21% |
| Boston Partners | 3.65% |
| Gagnon Securities, LLC | 3.41% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.05% |
| State Street | 8.51% |
| Vanguard Group | 8.26% |
Source: Nexqual, June 10, 2026 at 01:55 UTC.
From Caredx, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Each HeartCare test provides our proprietary Personalized Risk Report, combining measures of immune activation and graft injury for more precise risk assessment.
- Our manufacturing facility in Fremantle, Australia, was used to support the production, packaging and labeling of our proprietary AlloSeq brand kits.
- Intellectual Property Patents and Proprietary Technology To remain competitive, we seek to develop and maintain protection on the proprietary aspects of our technologies.
- Department of Health and Human Services, or HHS, has issued regulations to protect the privacy and security of protected health information, or PHI, and standardize data content, codes and formats used in healthcare transactions and the standardized identifiers used by healthcare providers, such as us, and health plans.  We have developed policies and procedures in view of these regulations.
Partnerships
- In March 2023, we entered into a license and collaboration agreement with a private entity pursuant to which we were granted an irrevocable, non-transferable right to commercialize its proprietary software, iBox, for the predictive analysis of post-transplantation kidney allograft loss in the field of transplantation for a period of four years with exclusive rights in the United States.
- In April 2020, we entered into a license agreement with Cornell University pursuant to which we were granted exclusive rights to four U.S. patents covering methods and technology for the measurement of gene expression in urine to diagnose kidney transplant rejection.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PSNL | Personalis, Inc. | USD 9.75 | ▼ 9.3% |
| TWST | Twist Bioscience Corporation | USD 70.06 | ▲ 1.21% |
| VCYT | Veracyte, Inc. | USD 49.24 | ▲ 1.05% |
| FATE | Fate Therapeutics, Inc. | USD 1.9 | ▼ 4.04% |
| ARCT | Arcturus Therapeutics Holdings | USD 7.16 | ▼ 1.92% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:55 UTC. This page is informational and not investment advice.